Coloplast A/S banner

Coloplast A/S
OTC:CLPBY

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
OTC:CLPBY
Watchlist
Price: 5.75 USD 0.35% Market Closed
Market Cap: $12.9B

Wall St Price Targets

CLPBY Price Targets Summary
Coloplast A/S

Wall Street analysts forecast CLPBY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLPBY is 7.4 USD with a low forecast of 6 USD and a high forecast of 9.85 USD.

Lowest Forecast
Price Target
6 USD
4% Upside
Average Forecast
Price Target
7.4 USD
29% Upside
Highest Forecast
Price Target
9.85 USD
71% Upside
Coloplast A/S Competitors:
Price Targets
CNTA
Centessa Pharmaceuticals PLC
12% Upside

Revenue
Forecast

7% / Year
Past Growth
6% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
7% / Year
Past Growth
6% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

7% / Year
Past Growth
3% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
7% / Year
Past Growth
3% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is 3%.

Operating Income
Forecast

5% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
5% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 7%.

Pre-Tax Income
Forecast

5% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
5% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 12%.

Net Income
Forecast

2% / Year
Past Growth
24% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
2% / Year
Past Growth
24% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 3 years is 24%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CLPBY's stock price target?
Price Target
7.4 USD

According to Wall Street analysts, the average 1-year price target for CLPBY is 7.4 USD with a low forecast of 6 USD and a high forecast of 9.85 USD.

What is the Revenue forecast for Coloplast A/S?
Projected CAGR
6%

Over the last 9 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Coloplast A/S?
Projected CAGR
3%

Over the last 9 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is 3%.

What is the Operating Income forecast for Coloplast A/S?
Projected CAGR
7%

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 7%.

What is the Pre-Tax Income forecast for Coloplast A/S?
Projected CAGR
12%

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 12%.

What is the Net Income forecast for Coloplast A/S?
Projected CAGR
24%

Over the last 9 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 3 years is 24%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett